Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises
source: Pediatric Emergency Care
year: 2019
authors: Hagedorn JM, Monico EC
summary/abstract:OBJECTIVES:
Sickle cell disease is the most common hemoglobin variant in the world and can present with recurrent vaso-occlusive painful crises. Pain control in these patients is often difficult and requires a multimodal approach. In patients with uncontrolled pain after traditional pain control methods, ketamine infusions have proven beneficial. Unfortunately, no source alone had described ketamine infusions for pediatric sickle cell patients. Our objective was to provide a thorough definitive reference for health care providers regarding the use of ketamine infusion for pain control in pediatric sickle cell painful crises.
METHODS:
Literature review.
RESULTS:
Low-dose ketamine infusions for pediatric patients with sickle cell disease painful crises resulted in improved pain scores and reduced opioid usage.
CONCLUSIONS:
Ketamine infusions have shown promise in assisting physicians in appropriately treating pediatric sickle cell painful crises.
DOI: 10.1097/PEC.0000000000000978
read more full text
+myBinderRelated Content
-
Cecelia R. Valrie, PhDDr. Cecelia Valrie is a developmental-he...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
-
Higher Prevalence of Hydroxyurea Use Is Associated with Lower Hospitalization Rate in a Population of Children with ...Background: Individuals with sickle cel...
-
William Owen, MDDr. William Owen is a pediatric hematolo...
-
Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemiaSilent cerebral infarction (SCI) is the ...
-
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformGlobal biotherapeutics leader CSL Behrin...
-
Novel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.